Wockhardt Reports Strong Quarterly Performance as Total Income Hits 960 Crore

Wockhardt Reports Strong Quarterly Performance as Total Income Hits 960 Crore

Wockhardt Reports Strong Quarterly Performance as Total Income Hits 960 Crore​

Wockhardt Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The company remains focused exclusively on the pharmaceutical business segment.

The Board of Directors approved these results during a meeting held on August 10, 2026. These findings have been subjected to a limited review by Statutory Auditors.

Financial Performance Highlights (Q Ended June 30, 2026)​

Wockhardt’s performance across both standalone and consolidated entities showed significant financial metrics for the quarter. The key income figures are summarized below in Indian Rupees (Rs.) Crore:

ParticularsStandalone Results (Unaudited)Consolidated Results (Unaudited)
Revenue from Operations929929
Other Income3131
Total Income960960
Net Profit after Tax (Attributable to Equity Shareholders)106107
Earnings per Share (Basic)6.55*6.55*

Expenses and Profitability​

The standalone financial results indicate Total Expenses amounted to 844 Crore for the quarter, with a Net Profit after tax attributable to equity shareholders standing at 106 Crore.

For the consolidated entity, total expenses were 844 Crore, resulting in a Net Profit after tax of 107 Crore attributed to equity shareholders.

Group Structure and Review​

The consolidated results encompass Wockhardt Limited (the Holding Company) and its extensive network of subsidiaries. The company maintains control over a wide array of entities across various geographies.

A list of major subsidiaries as of June 30, 2026 includes Wholly Owned Subsidiaries like Wockhardt UK Holdings Limited, Wockhardt Europe Limited, and Wockhardt Medicines Limited, alongside Step-Down Subsidiaries such as CP Pharmaceuticals Limited, Wallis Group Limited, and Wockhardt Nigeria Limited.

The statements were prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34).

WOCKPHARMA Stock Price Movement​

Shares of Wockhardt Limited settled today in the post-market session, shedding 2.87% or ₹58.00. The stock traded on a volume of 1.70 million shares as it closed down.
 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.

Last edited by a moderator:
Back
Top